ALK Inhibitor Outperforms Adjuvant Chemotherapy for Resected Lung Cancer

(MedPage Today) -- MADRID -- Disease-free survival (DFS) in resectable ALK-positive non-small cell lung cancer (NSCLC) improved by 76% with adjuvant alectinib (Alecensa) compared with chemotherapy, according to a randomized trial. Across disease...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news